An experimental weight-loss pill helped people lose up to 12% of their body weight in a mid-stage trial — the latest sign that the blockbuster GLP-1 class is moving from injections toward convenient once-daily tablets.
The drug, aleniglipron (from Structure Therapeutics), is a small-molecule oral GLP-1 medicine — chemically manufactured, unlike the peptide-based injectables Ozempic and Wegovy that require refrigeration. In a Phase 2b trial of 230 adults (average age 50) across 38 U.S. sites over 36 weeks, weight fell by 9.0% at the lowest dose, 10.7% at a middle dose and 12.1% at the highest — versus just 0.5% on placebo. The results were published August 10, 2026 in Nature Medicine.
Tolerability
As with other GLP-1 drugs, the main side effects were gastrointestinal (nausea and the like), described as mild to moderate and easing over time; about 10.4% of participants stopped treatment, and no drug-induced liver injury was reported. “The difference with aleniglipron is it’s a small molecule,” noted obesity expert Robert Kushner.
What’s next
Structure plans a Phase 3 trial with an adjusted dose-escalation schedule to improve tolerability. If oral GLP-1 pills can approach the results of injectables, they could dramatically widen access — easier to make, ship, store and take — in a market already reshaping medicine. These are mid-stage results, and larger trials will decide the drug’s ultimate place.